LUNDBECK, LLC
Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Lundbeck LLC
- Registration Number
- NCT01413711
A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01278173
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸Yale Medical Center, New Haven, Connecticut, United States
🇺🇸CNMRI, Dover, Delaware, United States
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 267
- Registration Number
- NCT01160770
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 108
- Registration Number
- NCT01128959
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Clinical Trials Incorporated, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Network, Inc., Torrance, California, United States
A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy
- Conditions
- Epilepsy
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 98
- Registration Number
- NCT01079351
- Prev
- 1
- 2
- Next
News
Lundbeck Advances Innovative Phase 3 Trial Design for Amlenetug in Multiple System Atrophy
Lundbeck will present details of its Phase 3 MASCOT trial for amlenetug, a first-in-class monoclonal antibody targeting α-synuclein aggregation in Multiple System Atrophy patients.
Zentalis Pharmaceuticals Appoints James B. Bucher as Chief Legal Officer to Support Azenosertib's Advancement
Zentalis Pharmaceuticals has appointed James B. Bucher as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, bringing over 30 years of life sciences legal experience.
FDA Reviewers Question Efficacy of Otsuka's Brexpiprazole-Zoloft Combination for PTSD Treatment
FDA staff reviewers have raised significant efficacy concerns over Otsuka Pharma's brexpiprazole combination therapy for PTSD, citing inconsistent trial results and modest treatment effects that may lack clinical meaningfulness.
Lundbeck's Lu AG13909 Receives Orphan Drug Designation for Congenital Adrenal Hyperplasia Treatment
Lundbeck received orphan drug designation from both the FDA and EMA for Lu AG13909, a novel humanized monoclonal antibody targeting ACTH for congenital adrenal hyperplasia treatment.
Lundbeck's Eptinezumab Shows Strong Efficacy in Asian Chronic Migraine Patients in Phase III SUNRISE Trial
H. Lundbeck A/S announced positive results from the SUNRISE phase III trial, demonstrating eptinezumab's efficacy in a predominantly Asian population with chronic migraine.
Pharmaceutical Industry Sees Wave of Board Appointments as Companies Strengthen Leadership
Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams.
Lundbeck Presents Phase II Data for Amlenetug in Multiple System Atrophy at International Congress
Lundbeck presented results from the AMULET phase II trial investigating amlenetug, a monoclonal antibody targeting α-synuclein, as a potential treatment for multiple system atrophy (MSA).
Migraine Treatment Pipeline Shows Robust Activity with 30+ Companies Advancing Novel Therapies Through Clinical Trials
DelveInsight's 2025 pipeline report reveals over 30 companies are actively developing more than 30 pipeline therapies for migraine treatment, indicating a robust therapeutic landscape.
Lundbeck's Vyepti Demonstrates Sustained Efficacy in Migraine Prevention at AAN 2025
New data presented at AAN 2025 shows Lundbeck's Vyepti provides sustained efficacy for migraine prevention, with significant improvements in patient-reported outcomes including brain fog reduction.
FDA Accepts Teva's Application for AJOVY in Pediatric Migraine Prevention, Potentially First CGRP Antagonist for Children
The FDA has accepted Teva Pharmaceuticals' supplemental Biologics License Application for AJOVY (fremanezumab) to expand its indication to include prevention of episodic migraine in children and adolescents aged 6-17 years weighing at least 45 kg.